Imagion Biosystems Limited
Imagion Biosystems Limited (IBX.AX) Stock Competitors & Peer Comparison
See (IBX.AX) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| IBX.AX | A$0.02 | -6.25% | 3M | -0.30 | -A$0.05 | N/A |
| SHL.AX | A$27.70 | -1.74% | 13.7B | 24.30 | A$1.14 | +3.86% |
| IDX.AX | A$2.67 | -1.84% | 993.8M | 133.50 | A$0.02 | +2.17% |
| HLS.AX | A$0.77 | -1.91% | 559.1M | -0.80 | -A$0.96 | +82.44% |
| ACL.AX | A$2.80 | -0.71% | 545.8M | 18.67 | A$0.15 | +4.46% |
| MVF.AX | A$0.79 | -0.63% | 307.8M | -79.00 | -A$0.01 | +6.46% |
| GSS.AX | A$0.33 | +0.61% | 75.4M | -3.32 | -A$0.10 | N/A |
| PEB.AX | A$0.09 | +0.00% | 69M | -2.83 | -A$0.03 | N/A |
| LDX.AX | A$0.07 | +8.96% | 54.6M | -7.30 | -A$0.01 | N/A |
| MAP.AX | A$0.09 | +0.00% | 47.4M | -3.07 | -A$0.03 | N/A |
Stock Comparison
IBX.AX vs SHL.AX Comparison July 2025
IBX.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IBX.AX stands at 3M. In comparison, SHL.AX has a market cap of 13.7B. Regarding current trading prices, IBX.AX is priced at A$0.02, while SHL.AX trades at A$27.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IBX.AX currently has a P/E ratio of -0.30, whereas SHL.AX's P/E ratio is 24.30. In terms of profitability, IBX.AX's ROE is +0.55%, compared to SHL.AX's ROE of +0.07%. Regarding short-term risk, IBX.AX is more volatile compared to SHL.AX. This indicates potentially higher risk in terms of short-term price fluctuations for IBX.AX.Check SHL.AX's competition here
IBX.AX vs IDX.AX Comparison July 2025
IBX.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IBX.AX stands at 3M. In comparison, IDX.AX has a market cap of 993.8M. Regarding current trading prices, IBX.AX is priced at A$0.02, while IDX.AX trades at A$2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IBX.AX currently has a P/E ratio of -0.30, whereas IDX.AX's P/E ratio is 133.50. In terms of profitability, IBX.AX's ROE is +0.55%, compared to IDX.AX's ROE of +0.01%. Regarding short-term risk, IBX.AX is more volatile compared to IDX.AX. This indicates potentially higher risk in terms of short-term price fluctuations for IBX.AX.Check IDX.AX's competition here
IBX.AX vs HLS.AX Comparison July 2025
IBX.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IBX.AX stands at 3M. In comparison, HLS.AX has a market cap of 559.1M. Regarding current trading prices, IBX.AX is priced at A$0.02, while HLS.AX trades at A$0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IBX.AX currently has a P/E ratio of -0.30, whereas HLS.AX's P/E ratio is -0.80. In terms of profitability, IBX.AX's ROE is +0.55%, compared to HLS.AX's ROE of -0.02%. Regarding short-term risk, IBX.AX is more volatile compared to HLS.AX. This indicates potentially higher risk in terms of short-term price fluctuations for IBX.AX.Check HLS.AX's competition here
IBX.AX vs ACL.AX Comparison July 2025
IBX.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IBX.AX stands at 3M. In comparison, ACL.AX has a market cap of 545.8M. Regarding current trading prices, IBX.AX is priced at A$0.02, while ACL.AX trades at A$2.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IBX.AX currently has a P/E ratio of -0.30, whereas ACL.AX's P/E ratio is 18.67. In terms of profitability, IBX.AX's ROE is +0.55%, compared to ACL.AX's ROE of +0.18%. Regarding short-term risk, IBX.AX is more volatile compared to ACL.AX. This indicates potentially higher risk in terms of short-term price fluctuations for IBX.AX.Check ACL.AX's competition here
IBX.AX vs MVF.AX Comparison July 2025
IBX.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IBX.AX stands at 3M. In comparison, MVF.AX has a market cap of 307.8M. Regarding current trading prices, IBX.AX is priced at A$0.02, while MVF.AX trades at A$0.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IBX.AX currently has a P/E ratio of -0.30, whereas MVF.AX's P/E ratio is -79.00. In terms of profitability, IBX.AX's ROE is +0.55%, compared to MVF.AX's ROE of -0.01%. Regarding short-term risk, IBX.AX is more volatile compared to MVF.AX. This indicates potentially higher risk in terms of short-term price fluctuations for IBX.AX.Check MVF.AX's competition here
IBX.AX vs GSS.AX Comparison July 2025
IBX.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IBX.AX stands at 3M. In comparison, GSS.AX has a market cap of 75.4M. Regarding current trading prices, IBX.AX is priced at A$0.02, while GSS.AX trades at A$0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IBX.AX currently has a P/E ratio of -0.30, whereas GSS.AX's P/E ratio is -3.32. In terms of profitability, IBX.AX's ROE is +0.55%, compared to GSS.AX's ROE of -0.39%. Regarding short-term risk, IBX.AX is more volatile compared to GSS.AX. This indicates potentially higher risk in terms of short-term price fluctuations for IBX.AX.Check GSS.AX's competition here
IBX.AX vs PEB.AX Comparison July 2025
IBX.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IBX.AX stands at 3M. In comparison, PEB.AX has a market cap of 69M. Regarding current trading prices, IBX.AX is priced at A$0.02, while PEB.AX trades at A$0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IBX.AX currently has a P/E ratio of -0.30, whereas PEB.AX's P/E ratio is -2.83. In terms of profitability, IBX.AX's ROE is +0.55%, compared to PEB.AX's ROE of -0.86%. Regarding short-term risk, IBX.AX is more volatile compared to PEB.AX. This indicates potentially higher risk in terms of short-term price fluctuations for IBX.AX.Check PEB.AX's competition here
IBX.AX vs LDX.AX Comparison July 2025
IBX.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IBX.AX stands at 3M. In comparison, LDX.AX has a market cap of 54.6M. Regarding current trading prices, IBX.AX is priced at A$0.02, while LDX.AX trades at A$0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IBX.AX currently has a P/E ratio of -0.30, whereas LDX.AX's P/E ratio is -7.30. In terms of profitability, IBX.AX's ROE is +0.55%, compared to LDX.AX's ROE of -0.59%. Regarding short-term risk, IBX.AX is less volatile compared to LDX.AX. This indicates potentially lower risk in terms of short-term price fluctuations for IBX.AX.Check LDX.AX's competition here
IBX.AX vs MAP.AX Comparison July 2025
IBX.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IBX.AX stands at 3M. In comparison, MAP.AX has a market cap of 47.4M. Regarding current trading prices, IBX.AX is priced at A$0.02, while MAP.AX trades at A$0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IBX.AX currently has a P/E ratio of -0.30, whereas MAP.AX's P/E ratio is -3.07. In terms of profitability, IBX.AX's ROE is +0.55%, compared to MAP.AX's ROE of -0.48%. Regarding short-term risk, IBX.AX is more volatile compared to MAP.AX. This indicates potentially higher risk in terms of short-term price fluctuations for IBX.AX.Check MAP.AX's competition here
IBX.AX vs IIQ.AX Comparison July 2025
IBX.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IBX.AX stands at 3M. In comparison, IIQ.AX has a market cap of 40.7M. Regarding current trading prices, IBX.AX is priced at A$0.02, while IIQ.AX trades at A$0.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IBX.AX currently has a P/E ratio of -0.30, whereas IIQ.AX's P/E ratio is -5.21. In terms of profitability, IBX.AX's ROE is +0.55%, compared to IIQ.AX's ROE of -0.36%. Regarding short-term risk, IBX.AX is more volatile compared to IIQ.AX. This indicates potentially higher risk in terms of short-term price fluctuations for IBX.AX.Check IIQ.AX's competition here
IBX.AX vs CTE.AX Comparison July 2025
IBX.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IBX.AX stands at 3M. In comparison, CTE.AX has a market cap of 36.6M. Regarding current trading prices, IBX.AX is priced at A$0.02, while CTE.AX trades at A$0.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IBX.AX currently has a P/E ratio of -0.30, whereas CTE.AX's P/E ratio is 18.75. In terms of profitability, IBX.AX's ROE is +0.55%, compared to CTE.AX's ROE of +1.33%. Regarding short-term risk, IBX.AX is more volatile compared to CTE.AX. This indicates potentially higher risk in terms of short-term price fluctuations for IBX.AX.Check CTE.AX's competition here
IBX.AX vs BDX.AX Comparison July 2025
IBX.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IBX.AX stands at 3M. In comparison, BDX.AX has a market cap of 22M. Regarding current trading prices, IBX.AX is priced at A$0.02, while BDX.AX trades at A$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IBX.AX currently has a P/E ratio of -0.30, whereas BDX.AX's P/E ratio is -2.00. In terms of profitability, IBX.AX's ROE is +0.55%, compared to BDX.AX's ROE of -0.90%. Regarding short-term risk, IBX.AX is less volatile compared to BDX.AX. This indicates potentially lower risk in terms of short-term price fluctuations for IBX.AX.Check BDX.AX's competition here
IBX.AX vs RHY.AX Comparison July 2025
IBX.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IBX.AX stands at 3M. In comparison, RHY.AX has a market cap of 16.3M. Regarding current trading prices, IBX.AX is priced at A$0.02, while RHY.AX trades at A$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IBX.AX currently has a P/E ratio of -0.30, whereas RHY.AX's P/E ratio is -5.60. In terms of profitability, IBX.AX's ROE is +0.55%, compared to RHY.AX's ROE of -0.76%. Regarding short-term risk, IBX.AX is more volatile compared to RHY.AX. This indicates potentially higher risk in terms of short-term price fluctuations for IBX.AX.Check RHY.AX's competition here
IBX.AX vs GTG.AX Comparison July 2025
IBX.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IBX.AX stands at 3M. In comparison, GTG.AX has a market cap of 5.7M. Regarding current trading prices, IBX.AX is priced at A$0.02, while GTG.AX trades at A$0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IBX.AX currently has a P/E ratio of -0.30, whereas GTG.AX's P/E ratio is -3.90. In terms of profitability, IBX.AX's ROE is +0.55%, compared to GTG.AX's ROE of -3.62%. Regarding short-term risk, IBX.AX is more volatile compared to GTG.AX. This indicates potentially higher risk in terms of short-term price fluctuations for IBX.AX.Check GTG.AX's competition here
IBX.AX vs WFL.AX Comparison July 2025
IBX.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IBX.AX stands at 3M. In comparison, WFL.AX has a market cap of 1.5M. Regarding current trading prices, IBX.AX is priced at A$0.02, while WFL.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IBX.AX currently has a P/E ratio of -0.30, whereas WFL.AX's P/E ratio is -0.10. In terms of profitability, IBX.AX's ROE is +0.55%, compared to WFL.AX's ROE of +11.65%. Regarding short-term risk, IBX.AX is more volatile compared to WFL.AX. This indicates potentially higher risk in terms of short-term price fluctuations for IBX.AX.Check WFL.AX's competition here